Tag: MMAE
Women with Highest Expression of Target Protein Benefited Most of Experimental...
The antibody-drug conjugate DMUC5754A, a novel trial drug of a relatively new class of agents developed by Genentech, a member of the Roche Group,...
Updated Data for Brentuximab Vedotin Shows Durable Complete Remission and Manageable...
Updated data from a pivotal trial of single-agent brentuximab vedotin (adcetris™,Seattle Genetics) in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL)...
European Medicines Agency Accepts Brentuximab Marketing Authorization Application
European Medicines Agency (EMA) has accepted the filing of the Marketing Authorization Application (MAA) for brentuximab vedotin (Adcetris™, Takeda Pharmaceutical and Millennium: The Takeda...
Pfizer and Seattle Genetics Agree on Antibody-Drug Conjugate Collaboration
Pfizer and Seattle Genetics, a clinical-stage biotechnology company focused on the development and commercialization of monoclonal antibody-based therapies for the treatment of cancer ,...
Phase I Trial of Loaded Antibody Establishes Dose, Catalogues Side Effects...
An antibody loaded with an anti-cancer agent produced complete or partial remissions in 38% of patients with relapsed or therapy-resistant Hodgkin lymphoma enrolled in...
